Kidneys From Donors With Incidental Renal Tumors
Mireía Musquera(Surgical Specialties (Canada)), Antonio Alcaraz(Hospital Clínic de Barcelona), Núria Esforzado(Hospital Clínic de Barcelona), Josep M. Campistol(Universitat de Barcelona), María J. Ribal(Hospital Clínic de Barcelona), David Paredes(Services Hospital), Lluís Peri(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Federico Oppenheimer(Hospital Clínic de Barcelona), M. C. Sebastià(Hospital Clínic de Barcelona)
Cited by 29
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
|European Urology|2020|2.2k
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
|European Urology|2016|1.5k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study)
|American Journal of Transplantation|2010|566